Dimiter S. Dimitrov

Aug 20, 2024 | nature.com | Guillem Pascual-Pasto |Kathrin Bernt |Adam J. Wolpaw |Dimiter S. Dimitrov |Brendan McIntyre |Anna M. Giudice

AbstractNovel chimeric antigen receptor (CAR) T-cell approaches are needed to improve therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid tumor that expresses cell-surface GPC2 and GD2 with a tumor microenvironment infiltrated by CD16a-expressing innate immune cells. Here we engineer T-cells to express a GPC2-directed CAR and simultaneously secrete a bispecific innate immune cell engager (BiCE) targeting both GD2 and CD16a.

Nov 8, 2023 | nature.com | Quinlen Marshall |John Warrington |Alvin Farrel |David Groff |Sarvind Tripathi |Son Nguyen | +3 more

AbstractThe majority of oncogenic drivers are intracellular proteins, constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes1. However, most cancers have a modest mutational burden that is insufficient for generating responses using neoantigen-based therapies2,3. Neuroblastoma is a paediatric cancer that harbours few mutations and is instead driven by epigenetically deregulated transcriptional networks4.

Nov 8, 2023 | nature.com | Quinlen Marshall |Sarvind Tripathi |Son Nguyen |Dimiter S. Dimitrov |Helena Shen |Nathan Kendsersky

Retraction to: Nature https://doi.org/10.1038/s41586-021-04061-6 Published online 3 November 2021The authors are retracting this manuscript because of an important experimental error we detected. The manuscript reported tetramer staining experiments showing that 10LH can interact with multiple HLA allotypes including the HLA-B*14:02/PHOX2B peptide complex (Fig. 1a, 3c).

May 5, 2023 | frontiersin.org | Dimiter S. Dimitrov |Peter Lowe |Juliette Trepreau |Taciana Manso

IntroductionCancer is the leading cause of mortality worldwide, accounting for an estimated 10 million deaths in 2020 (1). The immune system is intrinsically involved in the physiological fight against cancer, acting in the detection and elimination of the tumor. The capacity of malignant cells to express immunological checkpoint molecules on their surface is one strategy by which they avoid their destruction by the immune system.